Abstract:Background: Sepsis is triggered by pathogenic microorganisms, resulting in a systemic inflammatory response. Liver cirrhosis and sepsis create a vicious cycle: cirrhosis weakens immune function, raising infection risk and hindering pathogen clearance. Optimal treatment outcomes depend on understanding liver cirrhosis patients' sepsis risk factors. Thus, preventing sepsis involves addressing these risk factors. Therefore, early identification and understanding of clinical characteristics in liver cirrhosis patients with sepsis are crucial for selecting appropriate antibiotics. A case-control study using logistic regression was conducted to examine the prognostic value of amyloid A/lactate level monitoring in identifying sepsis risk factors in liver cirrhosis patients. Methods: From March 2020 to March 2022, 136 liver cirrhosis patients treated at our hospital were divided into a sepsis group (n = 35) and a non-sepsis group (n = 101) based on sepsis complications. General clinical data were collected. Univariate analysis screened for liver cirrhosis patients' sepsis risk factors. Multivariate logistic analysis was subsequently employed to evaluate the risk factors. Sepsis patients were followed up for a month. Based on prognosis, patients were categorized into a poor prognosis group (n = 16) and a good prognosis group (n = 19). Serum amyloid A (SAA) and blood lactic acid (BLA) levels were compared between the two groups. The receiver operating characteristic (ROC) curve was used to evaluate the prognostic value of both individual and combined SAA/BLA monitoring. Results: Patient data, including age, diabetes history, liver cancer, hepatic artery embolization, recent antibiotic use, invasive procedures within two weeks, APACHE II Scoring, ALB and SAA and BLA levels, were compared between the sepsis and non-sepsis groups, showing significant differences (P < 0.05). Logistic regression identified factors such as age ≥ 70, recent antibiotic use, recent invasive procedures, history of liver cancer, hepatic artery embolization history, high APACHE II scores, decreased albumin, and elevated SAA and BLA levels as independent sepsis risk factors in liver cirrhosis patients (P < 0.05). Among the 35 sepsis patients, 16 had a poor prognosis, representing an incidence rate of 45.71%. Serum SAA and BLA levels were significantly higher in the poor prognosis group than in the good prognosis group (P < 0.05). The AUC for serum SAA and BLA was 0.831 (95%CI: 0.738-0.924), 0.720 (95%CI: 0.600-0.840), and 0.909 (95%CI: 0.847-0.972), respectively. The combined diagnostic AUC was significantly higher than that of single factor predictions (P < 0.05). The predictive value ranked as follows: joint detection > SAA > BLA. Conclusion: In treating liver cirrhosis, prioritize patients with advanced age, a history of hepatic artery embolization, recent invasive operations, history of liver cancer, recent antibiotic exposure, high APACHE II scores and low albumin. Closely monitoring serum SAA and BLA levels in these patients can offer valuable insights for early clinical prevention and treatment.

Can blood serum amyloid A concentrations in horses differentiate synovial sepsis from extrasynovial inflammation and determine response to treatment?

Are serum amyloid A or D-lactate useful to diagnose synovial contamination or sepsis in horses?

Utility of serum amyloid A in monitoring clinical response to antimicrobial treatment in horses with bacterial pneumonia

Serum amyloid A as a marker to detect sepsis and predict outcome in hospitalized neonatal foals

Serum amyloid A in the diagnosis of feline sepsis

Procalcitonin and carbonylated protein concentrations in equine synovial fluid

A Clinical Investigation on Serum Amyloid A Concentration in Client-Owned Healthy and Diseased Cats in a Primary Care Animal Hospital

A-281 Comparison of C-reactive Protein, Procalcitonin, and Presepsin in Blood and Synovial Fluid as Diagnostic Biomarkers for Septic Arthritis

P066 Serum amyloid A – A Novel Biomarker of Ulcerative Colitis Disease Activity

Serum Amyloid A as a Potential Biomarker in Inflammatory Bowel Diseases, Especially in Patients with Low C-Reactive Protein

Amyloid A and lactic acid as a predictor in patients with sepsis in patients with liver cirrhosis

Synovial fluid D-lactate – a pathogen-specific biomarker for septic arthritis: a prospective multicenter study

Serum amyloid A levels in patients with liver diseases.

Correlations between serum amyloid A protein and C‐reactive protein in infectious diseases

Comparison of the Diagnostic Efficacy of SAA1, HBP, CRP，PCT and Cytokine Profiles for Predicting Infection in Pediatric Febrile Patients

Serum amyloid A for predicting prognosis in patients with newly diagnosed Crohn's disease

Specificity of two peripartum blood markers for early lactation acute uterine inflammation in pasture-fed, seasonal-calving dairy cows.

P452 Serum Amyloid A for Predicting Surgery and Disease Exacerbation in Patients with Newly Diagnosed Crohn’s Disease

Prognostic value of the biomarkers serum amyloid A and nitric oxide in patients with sepsis

Assessment of Urinary Interleukin-18 and Serum Amyloid A Efficacies against C-Reactive Protein in Diagnosis and Follow-up of Neonatal Sepsis

Evaluation of sodium hyaluronate therapy in induced septic arthritis in the horse